Avandia Advisory Committee: Can Poking Old Wounds Be Good For FDA?
This article was originally published in The Pink Sheet Daily
Executive Summary
Two advisory panels will revisit the question of whether FDA should withdraw GlaxoSmithKline’s Avandia from the market as a reevaluation of the cardiovascular trial produces results similar to the original findings; the data does not seem to offer much more clarity, but does give the agency a chance to argue it handled previous controversies well.